FIG.1



Control
F2
F6
Antagonist A Pk
ranibizumab
Absorbance (258nm)
Retention Time (min)
0
2
4
6
8
10
12

FIG.2



F2
F3
F6
ranibizumab Pk
Antagonist A
2.5
5
7.5
10
12.5
15
17.5
20
22.5
Retention Time (min)
Absorbance (215nm)

FIG.3



Antagonist A
F6
F5
F3
ranibizumab
ranibizumab Aggregate
Antagonist A
02.5
5
7.5
10
12.5
15
17.5
Retention Time (min)
Absorbance (280nm)

FIG.4



F2
F3
F5
F6
F7
F8
F9
F10
% Purity of Antagonist A
100
90
80
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG. 4

FIG.5



F2
F3
F5
F6
F7
F8
F9
F10
% Purity of ranibizumab
120
100
80
60
40
20
0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.6



F2
F3
F4
F5
F6
F7
F8
F9
F10
120.0
100.0
80.0
60.0
40.0
20.0
0.0
% Purity of Antagonist A
0
2
4
6
8
10
12
14
Timepoint (Weeks)

FIG.7



F2
F3
F4
F5
F6
F7
F8
F9
F10
% Purity of ranibizumab
120
100
80
60
40
20
0
0
2
4
6
8
10
12
14
Timepoint (Weeks)

FIG.8



F2
F3
F5
F6
F7
F8
F9
F10
% Purity of Antagonist A
100
90
80
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.9



F2
F3
F4
F5
F6
F7
F8
F9
F10
% Purity of ranibizumab
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
12
14
Timepoint (Weeks)

FIG.10



F2
F3
F4
F5
F6
F7
F8
F9
F10
120.0
100.0
80.0
60.0
40.0
20.0
0.0
% Purity of Antagonist A
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.11



F2
F3
F4
F5
F6
F7
F8
F9
F10
% Purity of ranibizumab
100
90
80
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.12



F2
F3
F5
F6
F7
F8
F9
F10
% Purity of Antagonist A
100
90
80
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
14
16
Timepoint (Weeks)

FIG.13



F2
F3
F5
F6
F7
F8
F9
F10
% Purity of ranibizumab
120
100
80
60
40
20
0
0
2
4
6
8
10
12
14
16
Timepoint (Weeks)

FIG.14



F2
F3
F4
F5
F6
F7
F8
F9
F10
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.15



F2
F3
F4
F5
F6
F7
F8
F9
F10
% Purity of ranibizumab
102
100
98
96
94
92
90
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.16B




FIG.16A




FIG.17A




FIG.17B




FIG.18



F2
F3
F4
F5
F6
F7
F8
F9
F10
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.19B




FIG.19A




FIG.20



F2
F3
F5
F6
F7
F8
% Purity of Antagonist A
100
90
80
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.21



% Purity of Antagonist A
100
80
60
40
20
0
0
1
2
3
4
5
Timepoint (Weeks)
F9
F10

FIG.22



F2
F3
F5
F6
F7
F8
F9
F10
% Purity of ranibizumab
120
100
80
60
40
20
0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.23



F2
F3
F4
F5
F6
F7
F8
F9
F10
% Purity of ranibizumab
100
90
80
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.24



F1
F11
F12
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
12
Timepoint (Weeks)

FIG.25A




FIG.25B




FIG.26B




FIG.26A




FIG.27A



37°C
Absorbance (280nm)
Retention Time (min)
0
2.5
5
7.5
10
12.5
15
17.5
Antagonist A
ranibizumab
Aggregate
ranibizumab
ranibizumab
F11

FIG.27B



ranibizumab
F11
Antagonist A
ranibizumab
Aggregate
ranibizumab
25°C
Absorbance (280nm)
0
2.5
5
7.5
10
12.5
15
17.5
Retention Time (min)

FIG.27C



ranibizumab
F11
Antagonist A
ranibizumab Aggregate
ranibizumab
Absorbance (280nm)
0
2.5
5
7.5
10
12.5
15
17.5
Retention Time (min)
4°C

FIG.28



% Purity of Antagonist A
100
90
80
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
14
16
18
Timepoint (Weeks)
4C
25C
37C

FIG.29



% Purity of ranibizumab
120
100
80
60
40
20
0
0
2
4
6
8
10
12
14
16
Timepoint (Weeks)
4C
25C
37C

FIG.30



4C
25C
37C
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
12
14
16
18
Timepoint (Weeks)

FIG.31



F6, 37C
F4, 37C
F6, 25C
F4, 25C
F6, 4C
F4, 4C
% Purity of ranibizumab
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
12
14
16
18
Timepoint (Weeks)

FIG.32



F25
F14
F19
bevacizumab
Antagonist A
mAU
140
120
100
80
60
40
20
0
Absorbance (253 nm)
52
50
75
100
125
Retention Time (min)

FIG.33



P18
P19
F22
bevacizumab
Antagonist A
mAU
100
100
100
100
100
100
100
0
0
5
10
15
20
25
Retention Time (min)
Absorbance (215 nm)

FIG. 34



F25
F18
F15
F19
bevacizumab
Antagonist A
mAU
600
500
400
300
200
100
0
Absorbance (214 nm)
0
25
50
75
100
125
Retention Time (min)

FIG.35



F13
F14
F15
F16
F17
% Purity of Antagonist A
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.36



F19
F20
F21
F26
% Purity of Antagonist A
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
2
4
6
8
10
12
14
Timepoint (Weeks)

FIG.37



F13
F14
F15
F16
F17
F22
F24
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
% Purity of bevacizumab
0
1
2
3
4
5
6
7
8
9
Timepoint (Weeks)

FIG.38



F19
F20
F21
F23
F26
% Purity of bevacizumab
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
24
6
8
10
12
14
Timepoint (Weeks)

FIG.39



F13
F14
F15
F16
F17
F23
F24
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.40



F19
F20
F21
F23
F26
110.0
100.0
90.0
80.0
70.0
60.0
50.0
% Purity of Antagonist A
0
2
4
6
8
10
12
14
Timepoint (Weeks)

FIG.41



F13
F14
F15
F16
F17
F22
% Purity of bevacizumab
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
1
2
3
4
5
6
7
8
9
Timepoint (Weeks)

FIG.42



F19
F20
P21
F23
% Purity of bevacizumab
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
12
14
Timepoint (Weeks)

FIG.43



F13
F14
F15
F16
F17
F22
% Purity of Antagonist A
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.44



F19
F20
F21
F23
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
% Purity of Antagonist A
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.45



F13
F14
F15
F16
F17
F23
% Purity of bevacizumab
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.46



F19
F20
F21
F23
% Purity of bevacizumab
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.47



F13
F14
F15
F16
F17
F22
120.0
100.0
80.0
60.0
40.0
20.0
0.0
% Purity of Antagonist A
0
2
4
6
8
10
Timepoint (Weeks)

FIG.48



F19
F20
F21
F23
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.49



F13
F14
F15
F16
F17
F22
F24
120.0
100.0
80.0
60.0
40.0
20.0
0.0
% Purity of bevacizumab
0
2
4
6
8
10
Timepoint (Weeks)

FIG.50



F19
F20
F21
F23
% Purity of bevacizumab
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.51



F19
F20
F21
F23
% Purity of Antagonist A
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.52



F19
F20
F21
F23
% Purity of bevacizumab
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.53



F13
F14
F15
F16
F17
F22
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.54



F19
F20
F21
F23
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.55



F19
F20
F21
F23
F24
F26
% Purity of bevacizumab
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
10
20
30
Timepoint (Weeks)

FIG.56



pH 4.0
pH 5.0
pH 6.0
pH 7.0
pH 8.0
% Purity of Antagonist A
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.57



pH 4.0
pH 5.0
pH 6.0
pH 7.0
pH 8.0
% Purity of bevacizumab
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.58



pH 4.0
pH 5.0
pH 6.0
pH 7.0
pH 8.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
% Purity of Antagonist A
0
2
4
6
8
10
Timepoint (Weeks)

FIG.59



pH 4.0
pH 5.0
pH 6.0
pH 7.0
pH 8.0
% Purity of bevacizumab
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.60A




FIG.60B




FIG.61A




FIG.61B




FIG.62A




FIG.62B




FIG.63A




FIG.63B




FIG.64



F12
F24
F25
F26
% Purity of Antagonist A
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.65



F18
F24
F26
% Purity of bevacizumab
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.66



F12
F24
F25
F26
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.67



F18
F24
F26
% Purity of bevacizumab
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
2
4
6
8
10
Timepoint (Weeks)

FIG.68



4C
25C
37C
% Purity of Antagonist A
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.69



4C
25C
37C
% Purity of bevacizumab
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.70



4C
25C
37C
% Purity of Antagonist A
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.71



4C
25C
37C
% Purity of Bevacizumab
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.72



F19, 37C
F25, 37C
F19, 25C
F25, 25C
F19, 4C
F25, 4C
% Purity of Antagonist A
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.73



F19, 37C
F25, 37C
F19, 25C
F25, 25C
F19, 4C
F25, 4C
% Purity of Antagonist A
120.0
110.0
100.0
90.0
80.0
70.0
60.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.74



F19, 37C
F18, 37C
F19, 25C
F18, 25C
F19, 4C
F18, 4C
% Purity of bevacizumab
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.75



F19, 37C
F18, 37C
F19, 25C
F18, 25C
F19, 4C
F18, 4C
% Purity of bevacizumab
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0
5
10
15
20
25
30
Timepoint (Weeks)

FIG.76



ranibizumab
F6
F8
F11
Relative TF expression
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
10 -7.5
10 -5.0
10 -2.5
10 0.0
10 2.5
Conc (nM)

FIG.77




Antagonist A
F6
F8
F11
Relative BTGF2 expression
1.5
1.0
0.5
0.0
10 -7.5
10 -5.0
10 -2.5
10 0.0
10 2.5
10 5.0
Conc (nM)

FIG. 78A



where R represents the following structure:

and n is about 450.

FIG. 78B





FIG. 78C






FIG. 78D



NaO
O=P
O
NH
N
O
O=P—ONa
NH
N
N
N
NH2
O=P—ONa
NH2
N
N
N
N
O=P—ONa
O
NH
N
O
O=P—ONa
NH2
N
N
O
O
F
F
F
E
E

FIG. 78E




FIG. 78F

FIG.79A



F27 at T=0
F27 at 5°C (vial)
F27 at 30°C (vial)
F27 at 5°C (syringe)
F27 at 30°C (syringe)
Particle Count (# / mL)
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
1≤x<2
2≤x<5
5≤x<10
10≤x<25
25≤x<50
50≤x<75
75≤x<100
Range (µm) of Equivalent Circular Diameter

FIG.79B



F27 at T=0
F27 at 5°C (vial)
F27 at 30°C (vial)
F27 at 5°C (syringe)
F27 at 30°C (syringe)
80
70
60
50
40
30
20
10
0
10≤x<25
25≤x<50
50≤x<75
75≤x<100

FIG.80A



F28 at T=0
F28 at 5°C (vial)
F28 at 30°C (vial)
F28 at 5°C (syringe)
F28 at 30°C (syringe)
Particle Count (# / mL)
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
1≤x<2
2≤x<5
5≤x<10
10≤x<25
25≤x<50
50≤x<75
75≤x<100
Range (µm) of Equivalent Circular Diameter

FIG.80B



F28 at T=0
F28 at 5°C (vial)
F28 at 30°C (vial)
F28 at 5°C (syringe)
F28 at 30°C (syringe)
250
200
150
100
50
0
10≤x<25
25≤x<50
50≤x<75
75≤x<100

FIG.81A



F29 at T=0
F29 at 5°C (vial)
F29 at 30°C (vial)
F29 at 5°C (syringe)
F29 at 30°C (syringe)
Particle Count (# / mL)
60000
50000
40000
30000
20000
10000
0
1≤x<2
2≤x<5
5≤x<10
10≤x<25
25≤x<50
50≤x<75
75≤x<100
Range (µm) of Equivalent Circular Diameter

FIG.81B



F29 at T=0
F29 at 5°C (vial)
F29 at 30°C (vial)
F29 at 5°C (syringe)
F29 at 30°C (syringe)
350
300
250
200
150
100
50
0
10≤x<25
25≤x<50
50≤x<75
75≤x<100

FIG.82A



F30 at T=0
F30 at 5°C (vial)
F30 at 30°C (vial)
F30 at 5°C (syringe)
F30 at 30°C (syringe)
Particle Count (# / mL)
70000
60000
50000
40000
30000
20000
10000
0
1≤x<2
2≤x<5
5≤x<10
10≤x<25
25≤x<50
50≤x<75
75≤x<100
Range (µm) of Equivalent Circular Diameter

FIG.82B



F30 at T=0
F30 at 5°C (vial)
F30 at 30°C (vial)
F30 at 5°C (syringe)
F30 at 30°C (syringe)
250
200
150
100
50
0
10≤x<25
25≤x<50
50≤x<75
75≤x<100

FIG.83A



F31 at T=0
F31 at 5°C (vial) - N/A
F31 at 30°C (vial)
F31 at 5°C (syringe)
F31 at 30°C (syringe)
Particle Count (# / mL)
250000
200000
150000
100000
50000
0
1≤x<2
2≤x<5
5≤x<10
10≤x<25
25≤x<50
50≤x<75
75≤x<100
Range (µm) of Equivalent Circular Diameter

FIG.83B



F31 at T=0
F31 at 5°C (vial) - N/A
F31 at 30°C (vial)
F31 at 5°C (syringe)
F31 at 30°C (syringe)
3500
3000
2500
2000
1500
1000
500
0
10≤x<25
25≤x<50
50≤x<75
75≤x<100

FIG.84A



F27 at T=0
F27 at 5°C (vial)
F27 at 30°C (vial)
F27 at 5°C (syringe)
F27 at 30°C (syringe)
F28 at T=0
F28 at 5°C (vial)
F28 at 30°C (vial)
F28 at 5°C (syringe)
F28 at 30°C (syringe)
F29 at T=0
F29 at 5°C (vial)
F29 at 30°C (vial)
F29 at 5°C (syringe)
F29 at 30°C (syringe)
F30 at T=0
F30 at 5°C (vial)
F30 at 30°C (vial)
F30 at 5°C (syringe)
F30 at 30°C (syringe)
F31 at T=0
F31 at 5°C (vial)
F31 at 30°C (vial)
F31 at 5°C (syringe)
F31 at 30°C (syringe)
217404
100000
90000
80000
70000
60000
50000
40000
30000
20000
10000
0
Particle Count (# / mL)
1≤x<2
2≤x<5
5≤x<10
Range (µm) of Equivalent Circular Diameter

FIG.84B



F27 at T=0
F27 at 5°C (vial)
F27 at 30°C (vial)
F27 at 5°C (syringe)
F27 at 30°C (syringe)
F28 at T=0
F28 at 5°C (vial)
F28 at 30°C (vial)
F28 at 5°C (syringe)
F28 at 30°C (syringe)
F29 at T=0
F29 at 5°C (vial)
F29 at 30°C (vial)
F29 at 5°C (syringe)
F29 at 30°C (syringe)
F30 at T=0
F30 at 5°C (vial)
F30 at 30°C (vial)
F30 at 5°C (syringe)
F30 at 30°C (syringe)
F31 at T=0
F31 at 5°C (vial)
F31 at 30°C (vial)
F31 at 5°C (syringe)
F31 at 30°C (syringe)
3044
Particle Count (# / mL)
400
350
300
250
200
150
100
50
0
10≤x<25
25≤x<50
50≤x<75
Range (µm) of Equivalent Circular Diameter

FIG.85




Relative BTG2 expression
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
10-5
10-3
10-1
101
103
Antagonist A [nM]
F32

FIG.86


Relative BTG2 expression
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
10-5
10-3
10-1
101
103
Antagonist A [nM]
F33
F34